Back to School: How biopharma can reboot drug development. Access exclusive analysis here
RDYN restructured and reduced headcount to 54 from 81. The company also said it will seek strategic alternatives, including
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury